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ABSTRACT
Introduction The emphasis on aesthetic outcomes and 
quality of life (QoL) has motivated surgeons to develop skin- 
sparing or nipple- sparing mastectomy (SSM/ NSM) for breast 
cancer treatment or prevention. During the same operation, a 
so- called immediate breast reconstruction is performed. The 
breast can be reconstructed by positioning of a breast implant 
above (prepectoral) or below (subpectoral) the pectoralis 
major muscle or by using the patients’ own tissue (autologous 
reconstruction). The optimal positioning of the implant 
prepectoral or subpectoral is currently not clear. Subpectoral 
implant- based breast reconstruction (IBBR) is still standard 
care in many countries, but prepectoral IBBR is increasingly 
performed. This heterogeneity in breast reconstruction 
practice is calling for randomised clinical trials (RCTs) to guide 
treatment decisions.
Methods and analysis International, pragmatic, 
multicentre, randomised, superiority trial. The primary 
objective of this trial is to test whether prepectoral IBBR 
provides better QoL with respect to long- term (24 months) 
physical well- being (chest) compared with subpectoral 
IBBR for patients undergoing SSM or NSM for prevention 
or treatment of breast cancer. Secondary objectives will 
compare prepectoral versus subpectoral IBBR in terms of 
safety, QoL and patient satisfaction, aesthetic outcomes 
and burden on patients. Total number of patients to be 
included: 372 (186 per arm).
Ethics and dissemination This study will be conducted in 
compliance with the Declaration of Helsinki. Ethical approval 
has been obtained for the lead investigator’s site by the Ethics 
Committee ‘Ethikkommission Nordwest- und Zentralschweiz‘ 
(2020–00256, 26 March 2020). The results of this study will 
be published in a peer- reviewed medical journal, independent 
of the results, following the Consolidated Standards of 
Reporting Trials standards for RCTs and good publication 
practice. Metadata describing the type, size and content of 
the datasets will be shared along with the study protocol and 
case report forms on public repositories adhering to the FAIR 
(Findability, Accessibility, Interoperability, and Reuse) principles.
Strengths and limitations of this study
 ► International, multicentre, randomised superiority 
trial, which has the potential to impact clinical prac-
tice in implant- based breast reconstruction (IBBR).
 ► The pragmatic design of this trial, developed using 
PRECIS tools, will reflect the variation of clinical 
practice thereby providing generalisable results.
 ► Patient advocates were intensely involved through-
out the trial design, which is reflected in the prima-
ry endpoint focusing on patient- reported outcome 
measures.
 ► Subpectoral IBBR is still standard care in many 
countries, but prepectoral IBBR is increasingly per-
formed, resulting in heterogeneity in breast recon-
struction practice that callis for randomised clinical 
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Trial registration number NCT04293146.
INTRODUCTION
Breast cancer affects 2.1 million women each year.1 Over-
treatment, distress and morbidity of patients with breast 
cancer are serious global challenges, and quality of life 
(QoL) of breast cancer patients can be optimised without 
jeopardising safety.2 3
The emphasis on aesthetic outcomes and QoL has 
motivated surgeons to develop skin- sparing or nipple- 
sparing mastectomy (SSM/NSM). During the same oper-
ation, immediate breast reconstruction is performed to 
minimise deformity and optimise QoL. The breast can 
be reconstructed by positioning a breast implant either 
above (prepectoral) or below (subpectoral) the pecto-
ralis major muscle or by using autologous tissue recon-
struction.4 5
Following broad introduction of immediate implant- 
based breast reconstruction (IBBR) in clinical practice 
in the late 1970s, the implants were originally positioned 
above the pectoralis major muscle after NSM and SSM 
to reconstruct the breast in its natural pocket (prepec-
toral positioning). Initially, however, this technique was 
associated with unacceptably high rates of complications, 
including implant loss due to skin necrosis or infection, 
implant exposure and capsular contracture.6 To decrease 
the risk of complications, the procedure has been modi-
fied to position the implant below the pectoralis major 
muscle. While two- staged IBBR (initial tissue expander 
placement later exchanged to implant) has been the 
traditional approach, one- stage direct implant placement 
has recently become standard care in many European 
countries.7–11
Compared with the subpectoral technique, the prepec-
toral positioning has been suggested to reduce discom-
fort with no differences in overall complication rates.12 13 
Indeed, since the prepectoral positioning of the implant 
respects the anatomic position of the breast and avoids 
surgical alterations to the pectoralis major muscle, it offers 
a variety of potential advantages including improved 
physical well- being, easier recovery and aesthetically, no 
animation deformity.
To date, major heterogeneity in breast reconstruction 
practice exists, as identified during the first Oncoplastic 
Breast Consortium (OPBC) consensus conference of 
specialised oncological, oncoplastic and reconstructive 
breast surgeons.2 The OPBC panel concluded that the 
heterogeneity in breast reconstruction practice calls for 
randomised clinical trials (RCTs) to evaluate the safest 
and most effective reconstruction techniques.
METHODS AND ANALYSIS
Aims
The main purpose of this trial is to evaluate whether 
prepectoral IBBR provides better QoL with respect to 
long- term (24 months) physical well- being of the chest 
compared with subpectoral IBBR for patients undergoing 
SSM or NSM (also including skin reducing techniques) 
for prevention or treatment of breast cancer. The primary 
endpoint is the patient- reported assessment of the QoL 
(BREAST- Q) scale ‘physical well- being: chest’ assessed 
24 months after mastectomy.14 The study is designed to 
prove superiority by four points between prepectoral and 
subpectoral IBBR, with an expected common standard 
deviation (SD) of 13 points.
Design
This pragmatic, multicentre, randomised, international 
superiority trial will compare two surgical strategies for 
IBBR in parallel with a 1:1 random allocation to prepec-
toral or subpectoral breast reconstruction (figure 1). 
A total of 372 patients will be recruited in over 20 sites 
in Europe, China and the USA. Following a pragmatic 
approach, randomly assigned IBBR will be performed 
according to the surgeons’ usual standard care by use of 
a one- stage or two- stage approach with or without adjunc-
tive mesh. The study duration is planned for thirteen 
years: approximately 2 years of recruitment, end of the 
main study and analysis of the primary objective after 24 
months of follow- up (FU) of the last patient, end of the 
extended oncological FU 10 years after inclusion of the 
last patient and end of the final analysis 1 year after that.
Participants
Participants are women from the age of 18 years under-
going therapeutic or risk- reducing NSM or SSM and 
IBBR with the ability to complete QoL questionnaires. 
Patients must be able to comprehend the character 
and personal implications of the study and give written 
informed consent before any protocol- specific procedure 
and trial preregistration. Both unilateral and bilateral 
surgery cases are included in the therapeutic, as well as 
the prophylactic setting. Randomisation will take place at 
the patient and not at the breast level, so that bilateral 
cases will have the same implant position for both breasts. 
Patients with no indication for IBBR according to clinical 
judgement of the treating surgeon, patients with use of an 
implant as place holder only for immediate delayed autol-
ogous reconstruction, as well as patients with intraoper-
atively inadequate skin flaps for prepectoral IBBR will 
be excluded before randomisation. Each patient will be 
informed that the participation in the study is voluntary 
and that she may withdraw from the study at any time and 
that withdrawal of consent will not affect her subsequent 
medical assistance and treatment.
Intervention and procedures
After written informed consent has been obtained by 
the local principal investigator and the inclusion and 
exclusion criteria have been confirmed patients will be 
preregistered. Patient information will be assessed in 
the screening visit as well as in FU visits. Prior to surgery, 
patients’ demographics, personal and medical history, 
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of the breast/axilla, previous oncological history and 
therapy, tumour characteristics (if applicable) will 
be recorded, and the BREAST- Q and baseline breast 
aesthetics evaluation (including photographs) will be 
conducted.
During the surgery (visit 1), after completion of NSM 
or SSM and before IBBR, the surgeon will determine 
the adequacy of the mastectomy skin flaps with regard 
to perfusion and viability for both surgical strategies. In 
the case this is adequate, patients will be randomised via 
the Clinical Data Management System (CDMS) secuTrial. 
Neither surgeons nor patients will be blinded to the trial 
allocation, but the central outcome assessment team will 
be blinded.
According to the pragmatic study design, the inter-
vention will not be standardised to assure flexibility for 
surgeons to perform IBBR that reflects the variability in 
usual care.15–17 However, the key aspects of the interven-
tion will be documented including the types of meshes, 
matrices, expanders and implants used to perform IBBR, 
as well as practical details on the handling of devices and 
technology such as type, number and location of sutures, 
drains and use of antibiotics.
The FU schedule of this trial is in line with the usual 
care FU visits of patients after IBBR in accordance with 
the pragmatic trial design and should therefore promote 
participant retention. Patients will be seen 10 days as well 
as 1, 6, 12, 18 and 24 months after the mastectomy and 
IBBR, examined according to local standards and asked 
to fill out the QoL- questionnaires. If patients would not 
routinely perform the follow- up at the site, these visits 
can also be performed remotely by mail/phone. Only the 
24 months visit will be required to be done at the sites 
for all patients. The use of optimising procedures and 
supporting measures, such as supportive bra or breast 
band, are at the full discretion of the treating physician 
and will be recorded. All additional procedures are 
allowed to improve breast aesthetics, both during primary 
and secondary surgery, including autologous fat grafting, 
mastopexy, as well as symmetrising procedures of the 
contralateral breast (eg, reduction mammoplasty) and 
will be documented in detail.
All treatments for complications are at the full discre-
tion of the treating physicians to prevent implant loss in 
case of wound healing disorders, skin necrosis or surgical 
site infection.
Further concomitant care including radiotherapy and 
systemic therapies is at the discretion of the treating physi-
cians and will be documented. The primary endpoint of 
the study will be assessed 24 months after mastectomy. 
Additional to the regular FU procedures, this visit will 
include a photographic documentation of the breast for 















pen: first published as 10.1136/bm






4 Kappos EA, et al. BMJ Open 2021;11:e045239. doi:10.1136/bmjopen-2020-045239
Open access 
central analysis of aesthetics by a blinded outcome assess-
ment team.
This pragmatic trial will mostly follow local standards, 
therefore the study specific procedures are limited to the 
randomisation and the assessment of:
1. Randomisation of the patient during the surgery.
2. Patient QoL and satisfaction using BREAST- Q (prima-
ry endpoint: Long- term physical well- being (chest), 
secondary endpoints: early physical well- being (chest), 
psychosocial well- being, sexual well- being, adverse ef-
fects of radiation, breast animation deformity, satisfac-
tion with breasts and satisfaction with implants) and 
EQ- 5D- 5L assessment of health status (Swiss sites only 
for economic evaluation) at each study visit in the first 
2 years after mastectomy and IBBR.
3. Surgical complications and thromboembolic events 
(details described under ‘adverse events’).
4. Breast aesthetics (evaluated by the patient, study physi-
cians and a central blinded outcome assessment team) 
at screening and 24 months after the surgery.
5. Burden on patients within 24 months after mastectomy 
with assessment of foreign body sensation, cold feeling, 
pain as well as the number of breast- related operative 
procedures, length of hospital stay and the number of 
outpatient visits.
After 24 months, patients move to an extended FU in 
the years 3–10, in order to be able to determine onco-
logical outcomes and long- term complications. Patients 
will be followed up by their oncological surgeon, oncolo-
gist or gynaecologist. The yearly extended FU will mostly 
be done by using routinely collected data (patient chart 
review). If patients do not visit the site regularly and the 
data can therefore not be obtained by chart review, after-
care physicians (performing the oncological FU) will be 
contacted by phone or patients can be contacted by phone 
to obtain the information for the following endpoints: 
Recurrence- free survival (RFS), burden on patients and 
long- term complications.
Adverse events
The main safety endpoint of the trial is ‘loss of expander 
or implant,’ at 24 months of follow up defined as an 
unplanned surgical removal of expander/implant with or 
without immediate replacement. It will be assessed within 
the first month particularly for safety monitoring and 
beyond that as ‘surgical complication’ as described below.
Adverse events of interest that will be documented 
include surgical complications and thromboembolic 
events. They will be assessed at each study visit within 24 
months of mastectomy and IBBR, covering both surgical 
stages in case of two- staged IBBR. Surgical complica-
tions (wound dehiscence, haematoma, seroma, infec-
tion, mastectomy skin flap/ nipple necrosis, implant/ 
expander exposure/extrusion, implant/ expander rota-
tion/ malpositioning, rippling, capsular contraction) will 
be evaluated according to the modified classification of 
Clavien- Dindo.18 Additionally animation deformity will 
be assessed as a surgical complication according to Spear 
et al.19 Thromboembolic events will be assessed according 
to Common Terminology Criteria for Adverse Events 
v5.04.20
Long- term complications will also be assessed during 
the extended FU in the years 3–10 as far as possible from 
chart review (including, seroma, implant/expander 
rotation/malpositioning, infection, capsular contrac-
tion, rippling, animation deformity, loss of expander or 
implant).
An annual safety report is submitted according to 
the national regulations once a year to the local ethics 
committees (EC) by the Sponsor- Investigator.
Reporting of serious adverse events
Trial intervention related serious adverse events (SAEs) 
are documented and reported immediately (within a 
maximum of 24 hours) to the sponsor–investigator of 
the study. SAEs related to (adjuvant) systemic therapy or 
planned hospitalisations for example, for the seconds- 
stage surgery or procedures to improve breast aesthetics 
are exempted from expedited reporting. If it cannot be 
excluded that the SAE is attributable to the intervention 
under investigation, the sponsor–investigator reports it to 
the respective EC according to national regulations.
Follow-up of (serious) adverse events
All adverse events will be followed until they have abated, 
or until a stable situation has been reached. Depending 
on the event, FU may require additional tests or medical 
procedures as indicated, and/or referral to a general 
physician or a medical specialist.
Outcomes and measurements
Primary endpoint of this study is long- term physical well- 
being of the chest, assessed by the respective BREAST- Q 
scale 24 months after mastectomy and IBBR.
Secondary safety endpoints are loss of expander or 
implant, surgical complications, thromboembolic events 
and RFS. Patient reported secondary endpoints are other 
QoL domains: early physical well- being (chest), psychoso-
cial well- being, sexual well- being, adverse effects of radi-
ation, animation deformity using the BREAST- Q, patient 
satisfaction with breasts and implants. Other endpoints 
are central assessment of breast animation deformity, 
capsular contracture and breast aesthetics as well as the 
burden on patients and health economics (for the Swiss 
sites). Interference of different dose distributions of radi-
ation therapy and its consequences on the distribution of 
local tumour recurrences will be assessed.
Present accrual and target accrual
By July 2021, twenty study sites have been initiated and over 
140 patients have been randomised. During a 21- month 
recruitment period, we plan to include 372 patients at over 
20 sites in Switzerland, USA, China, Austria, Germany, 
Hungary and Sweden. Two back- up strategies have been 
pre- specified in case of under- recruitment. First, esti-
mated versus actual accrual is continuously monitored for 
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already 6 months after opening the first site. If the trial is 
under- recruiting, the second back- up strategy includes an 
international site escalation. Further OPBC study centres 
will be prepared between months 6 and 12 for back- up 
opening during the second year of trial recruitment. A 
total of 14 additional international OPBC study sites have 
committed to participate in this case.
Statistical considerations
Methods of minimising bias
Randomisation will be performed using the method of 
minimisation to ensure a balance between patients to 
receive one of the two surgical strategies (prepectoral 
vs subpectoral IBBR) with a 1:1 allocation of a total of 
186 patients per treatment arm. Randomisation will be 
stratified by study site, SSM versus NSM and unilateral 
versus bilateral surgery. All other potential confounding 
factors including one- staged versus two- staged proce-
dures, performance of axillary surgery and use of biolog-
ical versus synthetic vs no mesh will be addressed at the 
analysis level. The randomisation procedure will be 
implemented by the Clinical Trial Unit of the University 
Hospital Basel into the CDMS secuTrial. The minimisa-
tion method which will ensure that allocation to one of 
the two treatment groups is balanced with respect to the 
three stratification factors. To avoid predictable alterna-
tion of treatment allocation, patients will be allocated 
with a probability of 80% to the treatment group that 
would minimise the imbalance between the two treat-
ment groups within each study site.
Selection bias at inclusion will be minimised by use of 
the well- defined criterion for inclusion ‘adult patients 
(≥18 years of age) undergoing NSM or SSM and IBBR 
in the therapeutic or risk- reducing setting’. Furthermore, 
only patients will be fully registered and randomised who 
qualify for both surgical strategies.
For the primary endpoint and other QoL assessments, 
validated questionnaires only will be used.
Blinding would not be successful in patients, who 
report the primary endpoint. Due to the nature of the 
surgical procedure, the surgical team cannot be blinded 
to the allocated surgical strategy either. The surgical 
team will follow all patients according to clinical stan-
dards including diagnosis and treatment of complica-
tions. A central and blinded outcome assessment team 
will determine the following secondary endpoints using 
pictures from before and 24 months after the mastec-
tomy: Animation deformity, capsular contraction (≥grade 
3) and breast aesthetics ( BCCT. core). This team will be 
profoundly trained by education, guidance and experi-
ence to assess all endpoints in a uniform and reproduc-
ible manner.
Unblinding of the secondary outcomes assessment 
team will not be necessary since it is the (not blinded) 
surgical team and aftercare physicians who are respon-
sible for diagnosis and treatment of complications.
Sample size
The sample size was determined for the primary endpoint 
‘physical well- being (chest)’ at 24 months. Based on 
observations from the BRIOS trial and observational 
studies,21–23 the observation of mean scores of 76 and 
80 points respectively are expected for subpectoral and 
prepectoral implants (score ranges 0–100, with higher 
indicating better QoL). The clinically relevant differ-
ence in BREAST- Q ‘physical well- being: chest’ score that 
should be detected in a superiority design is four points 
between prepectoral and subpectoral IBBR,24 25 with 
an expected common SD of 13 points. Based on these 
assumptions, a sample size of 334 patients provides a 
80% power for a two- sided t- test at level α=0.05. In order 
to compensate for a potential drop- out rate of 10%, the 
total sample size was calculated to include n=372 patients. 
Due to the primary analysis planning to include covari-
ates of prognostic importance in a regression model, an 
increase of the power with respect to the t- test may be 
expected.
Primary analysis
The main study analysis of the primary and most 
secondary objectives will occur after 24 months of 
follow- up of the last patient enrolled. The primary anal-
ysis will be performed on the full analysis set composed 
of all randomised patients following the intention- to- treat 
(ITT) principle. To compare the two treatment arms and 
test the primary hypothesis, a linear mixed model will 
be fitted with the BREAST- Q physical well- being (chest) 
score at 24 months as response variable, with treatment 
assignment as independent variable, and adjusted for 
the baseline BREAST- Q physical well- being (chest) score, 
stratification factors (ie, unilateral vs bilateral surgery and 
NSM vs SSM) and other factors potentially associated with 
the endpoint (eg, expected use of one- stage vs two- stage 
procedure, expected type of surgical mesh. Additionally 
a random intercept to account for the centre effect will 
be included. As a sensitivity analysis an unadjusted t- test 
will be performed on the BREAST- Q physical well- being 
(chest) score change from baseline to compare the two 
treatment arms.
Following the recommendations in Jakobsen et al, the 
following strategies for missing data will be adopted, 
under the missing at random assumption26:
1. Complete- case analyses will be performed if the pro-
portion of missing data is below 5% or if data are only 
missing in the outcome variable. In this case, also best- 
worst and worst- best case sensitivity analyses will be 
performed.
2. In the unlikely event that missingness exceeds 40% 
only a complete- case analysis will be reported, which 
cannot however be considered confirmative due to the 
extent of missingness.
3. Multiple imputation will be otherwise implemented.
To explore whether estimated treatment effects for the 
primary endpoint vary significantly between subcategories 
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of the BREAST- Q physical well- being (chest) score for each 
of the following baseline (presurgery) variables:
Unilateral versus bilateral surgery, NSM versus SSM 
procedure, expected use of postoperative radiation 
therapy, expected use of a one- staged versus two- staged 
procedure, expected type of mesh.
In addition, exploratory subgroup analyses will be 
considered for the following postrandomisation variables 
capturing actual treatment, interpreted with caution as they 
may be on the causal pathway between the intervention and 
the endpoint: Use of postoperative radiation therapy, one- 
staged versus two- staged procedure, biological matrix versus 
synthetic mesh versus neither matrix nor mesh.
Secondary analyses
The safety evaluation will be mainly based on the rate of 
loss of expander or implant for any reason or duration 
within 24 months. The expected rate of expander or 
implant loss is 10% for subpectoral and prepectoral IBBR, 
with an expected non- inferiority margin of 5%. Under 
these assumptions and with the planned sample size of 167 
patients per arm after potential drop- out, the power to show 
non- inferiority is very low (around 44%).27 Nevertheless the 
rate of loss of expander or implant will be estimated with 
its 95% CI according to treatment assignment, as well as 
for their difference with 95% CI. With the low expected 
frequency of an event, an exact binomial CI methodology 
will be implemented.
Similarly as described for the primary endpoint, a 
model based analysis will be conducted to adjust for 
relevant baseline covariates (eg, unilateral vs bilateral 
surgery, NSM vs SSM), using a logit link function for the 
regression model, as reasonable in consideration of the 
observed event frequency. At a minimum, the loss rates 
according to treatment assignment (and difference) will 
be estimated by stratum with 95% CIs; hypothesis testing 
of treatment- by- factor interaction is not anticipated.
Surgical complications and thromboembolic events, 
as well as animation deformity, capsular contracture and 
breast aesthetics, will be analysed similarly.
To test whether prepectoral IBBR leads to better QoL 
with respect to additional QoL outcomes and better 
patient satisfaction in the short- term and long- term as 
compared with subpectoral IBBR over 24 months, the 
analysis will implement mixed linear modelling of the 
serial time points.
The oncological safety of prepectoral IBBR will be 
assessed primarily on the basis of RFS. A 5- year RFS event 
rate is expected to be approximately 7.5% (ie, 5- year 
RFS of 92.5%) in both treatment groups. At the time 
of the main analysis, the 2- year rates will be estimated 
by Kaplan- Meier method with 95% CIs. With extended 
follow- up, 5- and 10- year rates will be estimated. After 10 
years, approximately 58 events are expected (assuming 
exponential distribution of RFS), to allow estimation of 
10- year RFS and treatment effect HR estimation using 
Cox regression according to subgroups, for example, 
stratification factors.
Additional analyses: translational research
A number of subprojects have been proposed, spanning 
a range of oncologic, therapeutic, surgical and economic 
questions. Additional questions to be investigated include:
1. Impact of prepectoral versus subpectoral IBBR on 
oncological safety (RFS).
2. Impact of NSM versus SSM on the local recurrence 
rate (LRR).
3. Impact of postoperative complications on LRR.
4. Impact of IBBR on dose distribution in target volumes 
and organs at risk (mainly ipsilateral lung and heart) 
in patients with postmastectomy radiation therapy.
5. Impact of mastectomy flap thickness on reconstruc-
tive complications related to breast reconstruction 
and oncological safety.
6. Impact of implant size and shape on risk of complica-
tions and QoL.
7. Impact of preoperative breast cup size and ptosis on 
risk of complications, QoL and oncological safety.
8. Impact of surgical one- team versus two- team ap-
proach on risk of complications and oncological 
safety.
9. Impact of prepectoral versus subpectoral IBBR on 
risk of early complications.
10. Health economics analysis of the Swiss sites to com-
pare burden on patients and assess the incremental 
costs and the incremental cost effectiveness ratio of 
the respective surgical strategies.
11. Impact of prepectoral versus subpectoral IBBR on 
breast animation deformity assessed by the new 
BREAST- Q scale versus objective photographical 
assessment.
Monitoring and data safety monitoring board
The trial is following a risk- adapted monitoring approach, 
which is described in detail in the study monitoring plan. 
The safety of the trial will be evaluated twice- yearly by the 
independent data safety monitoring board of the Interna-
tional Breast Cancer Study Group, consisting of a study- 
independent statistician, three independent breast cancer 
oncologist experts, a patient advocate and a surgeon with 
expertise in IBBR.
Patient and public involvement
Patient advocates were involved in the whole process 
of developing this protocol and two of them are coau-
thors of this manuscript as well. Patients prioritised and 
decided the primary outcome of this study. The results 
of this study will be made available to study participants 
after publication in form of the scientific manuscript. The 
burden of the intervention was also be assessed by our 
patient advocates.
DISCUSSION
All published studies on prepectoral IBBR are small and 
observational.12 13 22 28–32 They predominantly suggest 
that prepectoral IBBR is safe and effective. Baker et al 
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authors compared prepectoral versus subpectoral IBBR 
performed preferably in one stage and found no relevant 
differences in mean short- term pain scores (1.5 vs 1.5; 
p=0.45) and mean mid- term BREAST- Q scores (72 and 71; 
p=0.81).22 Sbitany et al emphasised in a retrospective study 
that the main benefit of prepectoral IBBR is the elimina-
tion of pectoralis major muscle alteration and animation 
deformity.29 They showed data suggesting the lack of a 
difference between the prepectoral and the subpectoral 
approach in terms of overall complication rate (17.9% 
vs 18.8%; p=0.49). Bettinger et al retrospectively investi-
gated 213 patients undergoing prepectoral IBBR versus 
subpectoral IBBR with acellular dermal matrix (ADM) 
versus subpectoral IBBR without ADM and found numer-
ically lower rates of complications, although not signifi-
cant, in the prepectoral compared with the subpectoral 
ADM- based group (adjusted risk ratio: 0.25; 95% CI 0.06 
to 1.00).28 However they did not evaluate PROs in this 
single- centre trial. Jafferbhoy et al reported an implant 
loss rate of 10.2% and a mean length of stay of 1.48 days 
in a series of 78 NSM procedures with one- staged prepec-
toral positioning of implants by using a newer ADM called 
Braxon.30 They concluded that the advantages of prepec-
toral IBBR are quicker postoperative recovery and short 
post- operative hospital stay, and that long- term studies 
are required to assess rippling, postoperative animation, 
capsular contracture and impact of radiotherapy. Siga-
love et al reported low rates of complications in a series 
of 353 prepectoral predominantly two- staged reconstruc-
tions including infection, seroma and skin flap necrosis, 
each occurring at an incidence of less than 5%.12 They 
discussed that the advantage of prepectoral reconstruc-
tion is the absence of muscle elevation which may decrease 
animation deformity caused by muscle contraction, chest 
tightness, pain and muscle spasm and the avoidance of 
an unnatural state by subpectoral placement. Woo et al 
reported a series of 135 prepectoral predominantly two- 
staged IBBR with 87% of patients having an uneventful 
recovery without complications.13 They discussed that 
the primary benefit of prepectoral IBBR using ADM is 
the precise control of the breast pocket, simultaneously 
avoiding any animation deformity.
Given this lack of clear scientific evidence, clinical deci-
sion making in IBBR is very heterogeneous. Subpectoral 
IBBR is still standard care in many countries, but prepec-
toral IBBR is increasingly performed. This heterogeneity 
in breast reconstruction practice is calling for RCTs like 
this one to guide treatment decisions.
This trial compares prepectoral to subpectoral IBBR 
with the hypothesis that prepectoral approach is supe-
rior in terms of physical well- being of the chest at 24 
months. The aim is to adhere to standard of care as 
much as possible to follow the pragmatic trial design to 
generate data that are applicable to today’s practice. Its 
randomised study design and pragmatic nature will make 
this current study unique in its applicability and feasibility 
for different centres across the world. The study findings 
will make a significant impact in clinical decision making 
and surgical standards worldwide in the field of evolving 
IBBR.
ETHICS AND DISSEMINATION
Risks and benefits of study participants are described 
above. This study will be conducted in compliance with 
the protocol, the current version of the Declaration of 
Helsinki, the ICH- GCP, the HRA as well as other locally 
relevant legal and regulatory requirements.
Before the start of the trial, the trial protocol, informed 
consent document and any other appropriate docu-
ments were submitted to the respective independent ECs. 
Ethical approval has been obtained for the lead investi-
gator’s site by the EC ‘Ethikkommission Nordwest- und 
Zentralschweiz‘ (2020–00256, 26 March 2020). Substan-
tial changes to the study setup and study organisation, the 
protocol and relevant study documents are submitted to 
the EC for approval before implementation.
Before being admitted to the clinical trial, all subjects 
must consent in writing to participate after the nature, 
scope and possible consequences of the clinical trial have 
been explained in a form understandable to her. The 
further use of the trial data is requested from trial partic-
ipants in a separate consent form.
The results of this study will be published in a peer- 
reviewed medical journal, independent of the results, 
following the Consolidated Standards of Reporting Trials 
standards for RCTs and good publication practice. Meta-
data describing the type, size and content of the datasets 
will be shared along with the study protocol and case 
report forms on public repositories adhering to the FAIR 
principles (Findability, Accessibility, Interoperability, and 
Reuse).
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